We previously wrote a detailed overview of the MiniMed 780G Artificial Pancreas and key features, and today we want to share you with the latest key data released on the MiniMed 780G Artificial Pancreas at the 2021 Virtual Diabetes Conference.
In March 2021, Medtronic shared the latest results of their artificial pancreas, the Medtronic 780G, and here is the data:
Medtronic MiniMed 780G Study Results
- No severe hypoglycemia and diabetic ketoacidosis
- Average A1C of 7.0%
- Overall time in range (defined as 70-180 mg/dL) of 75%, with overall time below range (defined as less than 70 mg/dL) of 1.8%
- Overnight time in range of 82%, with overnight time below range of 1.5%
- Autocorrection contributing to 22% of all bolus insulin
- Participants being in SmartGuard (closed loop) 95% of the time
- Mean sensor glucose of 148 mg/dL overall, and 144 mg/dL at the default 100mg
Medtronic MiniMed 780G Study Results In More Challenging Patients
Medtronic conducted another study in New Zealand with more challenging diabetes patients, defined as those with poorer control, as well as children 7 years old and above. How did the Minimed 780G do in that setting? Here are the results:
- Overall improvement of 13 percentage points for time in range to 70.4%
- A 0.4% overall decrease in time below range (70mg/dL) to 2.1%
- A 16% improvement in time in range overnight, due in large part to a 12% reduction in hyperglycemia
- A 13.0% improvement in time in range to 70.2% at the default 100mg/dl target
- Autocorrection contributing to 21% of all bolus insulin
- Participants being in SmartGuard (closed loop) 95% of the time
Study participants reported being highly satisfied with this system and how well it managed to automatically control their blood sugar with little to no input. The automated blood sugar control seems to be working very well, and leads to much better blood sugar control compared to manually managing blood sugar.
These study results are really encouraging as it will make life for those with type 1 diabetes much easier. However, at the time of writing (April 2021) the MiniMed 780G is still not available for sale in the United States or Canada as it is still going through the approval process. However, this study is really encouraging and should help Medtronic receive approval, hopefully soon.
We will keep an eye out on this and will share information as it becomes available for sale in the United States and Canada.
Source: MMDI Online
Onwards and Upwards 🙂